Payment overview · 2025
General Payments
$14,962.78
46 reported records · 14 companies
Healthcare provider profile · identity verified
Eugene Chung, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Advanced Heart Failure and Transplant Cardiology · CINCINNATI, OH · NPI 1003893926
Verified facts
What the public records show
CMS Open Payments records show Eugene Chung, M.D. received $14,962.78 in general payments during 2025 across 46 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 79.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Verquvo.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 365 claims for Jardiance by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11,831.09 | 79.1% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,650.00 | 11.0% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $328.86 | 2.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $235.14 | 1.6% | 9 | 2025 |
| Ancora Heart, Inc. | Unresolved — no canonical attribution shown | $185.67 | 1.2% | 3 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $175.56 | 1.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$150.96 | 1.0% | 5 | 2025 |
| BrioHealth Solutions, Inc. | Unresolved — no canonical attribution shown | $148.49 | 1.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $82.16 | 0.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.90 | 0.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $50.09 | 0.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.18 | 0.2% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $22.65 | 0.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $19.03 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,050.00 | 5 |
| Food and Beverage | $1,707.18 | 33 |
| Education | $205.60 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $13,481.09 | 14 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $328.86 | 2 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $205.60 | 8 | 2025 |
Source payment records
|
|||||
| AccuCinch Normalized: accucinch |
Device | Ancora Heart, Inc. | $185.67 | 3 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $175.56 | 3 | 2025 |
Source payment records
|
|||||
| BRIOVAD Normalized: briovad |
Device | BrioHealth Solutions, Inc. | $148.49 | 1 | 2025 |
Source payment records
|
|||||
| REVEAL LINQ Normalized: reveal linq |
Device | Medtronic, Inc. | $84.48 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $82.16 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $66.48 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.90 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $29.54 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $27.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.18 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $22.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 365 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
365 | 109 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
217 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
365 | 109 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Spironolactone | Spironolactone | 448 | 163 |
| Jardiance | Empagliflozin | 365 | 109 |
| Entresto | Sacubitril/Valsartan | 356 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 267 | 97 |
| Eliquis | Apixaban | 217 | 45 |
| Atorvastatin Calcium | Atorvastatin Calcium | 168 | 53 |
| Torsemide | Torsemide | 167 | 63 |
| Carvedilol | Carvedilol | 148 | 55 |
| Furosemide | Furosemide | 138 | 52 |
| Losartan Potassium | Losartan Potassium | 111 | 42 |
| Farxiga | Dapagliflozin Propanediol | 78 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 27 |
| Warfarin Sodium | Warfarin Sodium | 76 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 25 |
| Xarelto | Rivaroxaban | 62 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 20 |
| Eplerenone | Eplerenone | 46 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 41 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 14 |
| Valsartan | Valsartan | 38 | 15 |
| Potassium Chloride | Potassium Chloride | 36 | 13 |
| Digoxin | Digoxin | 35 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 34 | 17 |
| Ozempic | Semaglutide | 32 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 28 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Lisinopril | Lisinopril | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Verquvo | Vericiguat | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Metformin Hcl | Metformin Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,962.78 · 46 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AccuCinch, BRIOVAD, Barostim Neo System, CAMZYOS, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, JARDIANCE, Kerendia, LINQ II, LifeVest, REVEAL LINQ, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TRICLIP, VERQUVO, WINREVAIR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error